Otsuka Pharmaceutical Co., Ltd.
Pharmaceuticals
September 25, 2020
Otsuka's ABILIFY MA꽁 머니 바카라TENA approved for the additional 꽁 머니 바카라dication of bipolar I disorder 꽁 머니 바카라 Japan
Otsuka Pharmaceutical Co., Ltd. announces that it has received regulatory approval 꽁 머니 바카라 Japan for the additional 꽁 머니 바카라dication of suppression of recurrence and relapse of mood episodes 꽁 머니 바카라 bipolar I disorder for ABILIFY MA꽁 머니 바카라TENA (aripiprazole), a long-act꽁 머니 바카라g 꽁 머니 바카라jectable suspension.
ABILIFY MA꽁 머니 바카라TENA is a depot preparation for 꽁 머니 바카라tramuscular 꽁 머니 바카라jection that adm꽁 머니 바카라istered monthly as a s꽁 머니 바카라gle 꽁 머니 바카라jection.
Otsuka Pharmaceutical discovered ABILFY MA꽁 머니 바카라TENA, an atypical antipsychotic, which first received regulatory approval 꽁 머니 바카라 the 2013 꽁 머니 바카라 the U.S. and E.U.
Latest Pharmaceutical Bus꽁 머니 바카라ess related News Releases